EE282 Financial Burden of Progression of Chronic Myeloid Leukemia (CML) Patients Who Failed Two or More Tyrosine Kinase Inhibitors Treatment in the Brazilian Private Market Perspective
Year: 2023
Type: conference-abstract
Source: Value in Health
Authors: H. Kim, V. Silva, D. de Oliveira, D. Kashiura
Institution: Novartis (Switzerland)
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: bronze
OpenAlex ID: W4380149865
